The ATHANA alliance is approaching completion of the first phase of its work, which aims to develop novel antifungal therapies through targeted transport of active pharmaceutical ingredients (APIs) by an innovative nanoparticle technology. High‑potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) is responsible for stability testing and regulatory issues relating to a future transition to the GMP (Good Manufacturing Practice) environment. With the main project milestone (proof of concept) close to being achieved, the founding phase of the project remains on schedule for completion by May 2026.
ATHANAHAPILA reaching first phase completion of ATHANA nanoparticle antifungal Project
